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dergone hysterectomy showed evidence of better health than non-users on some dimensions. In the whole sample, however, there were no appreciable differences in social class and self reported health indicators between users and controls. The ratio of benefit to risk for long term use of hormone replacement therapy (HRT) in postmenopausal women is a question of great public interest. Estimates from observational studies'2 suggest that sustained use of HRT could reduce the incidence of myocardial infarction by up to 50%, and substantially reduce morbidity and mortality from fractures associated with osteoporosis. These benefits have to be weighed against possible increases in the risk of breast cancer and endometrial cancer.
Daly et al' have considered these issues in detail
and have shown that, on the basis of present knowledge, it is likely that benefits outweigh risks.
Three main concerns have, however, checked enthusiasm for increased use of HRT as a method of disease prevention. The first is that data on benefits and risks come exclusively from observational studies, and selection of healthier women to receive treatment may exaggerate the apparent benefits of HRT. The second concern is that those studies which have reported favourably on the effects of HRT have largely considered the use of unopposed oestrogen. In current clinical practice women who have not undergone hysterectomy usually receive oestrogens combined with some form of progestagen, to protect against endometrial cancer. Recent data suggest that these combinations may exert beneficial effects on some cardiovascular risk factors,4 but there remains concern that progestagens will reduce the protective effects of unopposed oestrogens, especially on serum lipids.5 Differences in type of hormone, dose, and duration of treatment, and in the use of cyclic or continuous combination regimens also confound the issue. The third concern is that it is largely unknown whether the benefits and risks of HRT are confined to current or recent users, or whether they are also apparent in past users.
These uncertainties have led to calls for large scale randomised trials of HRT."6 Through 43% of subjects were using combined therapy, found lower overall mortality and a lower risk of death from cardiovascular disease than expected on the basis of national rates.89 However, this study lacked power to detect rarer outcomes. In particular, the suggestion of an increased risk of mortality from breast cancer with increasing duration since first use of HRT could not be confirmed because of insufficient numbers.
The study was also limited by a lack of internal controls, a particular problem because of probable selection bias in the method of recruitment through specialised menopause clinics. A British case-control studyl' found increased risks of myocardial infarction and stroke in women taking unopposed oestrogen and near baseline risk in those taking combined therapy. A recent Scandinavian cohort study of 23 000 women prescribed HRT, using record linkage between prescription and hospital admission data," reported a 50% reduced risk of myocardial infarction for those using combined therapy, but found evidence of significant selection bias when a sample of cohort women were compared with a sample of non-users drawn from the general population. This study also lacked internal controls: rates in users were compared with expected rates based on incidence rates of myocardial infarction in the whole population of the Uppsala region, so that direct adjustment for confounders could not be made in the analyses.
As an alternative to a randomised trial, a cohort study of HRT ( 2) H = hysterectomy; BSO = bilateral salpingo-oophorectomy; OSU= ovarian status unknown tionnaire enquired about the history of HRT use, past experience of medical events that might have led to hospital admission, height and weight, menopausal status, smoking status, exercise habits, family history of cardiovascular disease, level of education, home ownership, occupation of subject and spouse, history of long term chronic illnesses, and consent to examine medical records. A subset of women was sent a longer questionnaire asking for additional information on alcohol intake, diet, history of fracture or osteoporosis, and questions about menopausal symptoms.
In this analysis, data from the questionnaires completed by consenting women were used to compare those using HRT with controls, with further analysis by hysterectomy status, to determine whether they differed in terms of characteristics known, or suspected, to confound the relationship between exposure and cardiovascular disease or cancer. Social class was 
Results
The prevalence of current HRT use was 14-7% and that of long term use was 10-1 % in women aged 45-64. Altogether, 2964 potential subjects were identified in the 17 participating practices -1482 long term users of HRT and 1482 nonuser controls. Totals of 1037 (70%) ofthe users and 819 (55 3%) of the controls completed the questionnaires. Table 1 shows the relationship between hysterectomy status, presence or absence of the ovaries, and use of HRT. Information on hysterectomy status was missing for 17 women who entered the study. Of the remainder, 422 (41%) ofthe users had a history of hysterectomy compared with 123 (15 2%) of controls (difference 25-8%, 95% confidence interval (CI) 21-9, 29-7%, p<0.001). One hundred and forty (13 5%) of the users had a history of bilateral oophorectomy compared with 21 (2 6%) ofthe controls (difference 11%, 95% CI 8-6, 13-4%, p<0-001). Among current users of HRT, 95-5% of women who had undergone hysterectomy were using unopposed oestrogen preparations and 96-3% of women with intact uteri were using some form of oestrogen/progestagen combination. Since the presence or absence of the uterus is such an important determinant in the prescribing decision, further comparisons between users and controls were made according to hysterectomy status.
WOMEN WITH A HISTORY OF HYSTERECTOMY
In women who had undergone hysterectomy, the mean (SD) age of users was 54-41 (4 82) years and that ofcontrols was 55 7 (4 87) years. Reported demographic and clinical characteristics of the two groups are shown in table 2. There was no significant difference in social class distribution between the two groups in relation to occupation, housing status, or age of leaving full time education. There were no significant differences in marital status, smoking status, body mass index, exercise habits, personal history of hypertension, or in alcohol use in the subset of patients who reported on this. Family history of breast cancer and heart disease were comparable in the two groups. Users were more likely than controls to have undergone bilateral oophorectomy (difference 16 Table 4 shows selected characteristics of participants, expressed as percentages, compared with contemporaneous data from the general United Kingdom population.14 Participants in the study, both users and controls, were of higher social class and in general exhibited more healthy behaviours than the general population.
Discussion
A survey of general practitioners conducted in 1989-90 estimated that about 9% of female patients aged 40-64 were receiving HRT.'5 Our study shows that the prevalence of postmenopausal HRT use remains low. In the absence of clear evidence about the ratio ofbenefit to risk, enthusiasm for this treatment among British general practitioners and their patients continues to be guarded. As expected most, but not all, women with a history of hysterectomy were taking unopposed oestrogen, and those with no history of hysterectomy were taking combined oestrogen/progestagen therapy, confirming estimates in previous surveys. '5 This is an important point to consider in planning observational studies. Direct comparison of the effects of opposed and unopposed oestrogen in women with the same hysterectomy status, which has been proposed as a comparison within a randomised trial,'5 is unlikely to be possible using observational data. 20 23 A tendency for the use of HRT to be prescribed more equally across the social spectrum has been noted in some recent surveys, 2528 and a diffusion of attitudes from better to less educated women has been proposed as an explanation.28 This trend is partly supported by our data, in which there were no significant differences between the two groups on a number of measures of social class in the cohort as a whole. Social class does, however, seem to be a factor in more discretionary treatment decisions. On the basis of occupation and home ownership, among those who had not undergone hysterectomy, higher social class women were more likely to receive HRT, usually an oestrogen/progestagen combination. Users in both groups were significantly more likely to be previous users of oral contraceptives, an effect found in several other studies.22242529 This could indicate a bias towards healthier women, or might be, as previously suggested,24 a behavioural effect, with women who have previous experience of taking exogenous hormones being more willing to consider use of postmenopausal hormones. Users who had not undergone hysterectomy were also more likely than controls to have had a mammogram at age 50. This difference was not seen in patients with a hysterectomy, and provides further evidence that women taking combined therapy may exhibit more health conscious behaviours than non-users. Increased contact with health professionals for monitoring of treatment may also be a factor in increasing uptake of preventive procedures in this group.
Comparisons between users and controls may have been affected by the different rates ofresponse to questionnaires in the two groups. Part of this difference is likely to be due to a higher proportion of "ghosts" among controls (that is, patients who never received the questionnaire because they had moved or died). o HRT users were unlikely to fall into this category because they were defined by their recent contact with the practice for dispensing ofmedication. The alternative explanation, that there is a correlation between interest in health and willingness to participate in research is also plausible. Such a bias could understate differences between users and non-users in the population, though paradoxically it may ensure greater validity of comparisons between users and controls within a cohort study.
A well conducted randomised trial has the greatest likelihood of eliminating known and, particularly, unknown confounding factors in allocation of treatment. It is unclear whether it will be possible to mount such a trial of HRT. Our study has shown the feasibility of a quick and inexpensive method of recruiting long term users of HRT and controls to an observational study through general practice. It is likely that the standard of data recording required by VAMP can only be met in better organised and funded practices, which in turn are less likely to serve deprived populations. This was reflected in a demographic profile of the sample as a whole which was not representative of the general population. Although raising issues of generalisability, this bias should not affect the validity of a cohort study, provided internal controls are included. Our study shows that computerised records can also be used effectively to recruit women who are non-users to act as controls. In a further analysis in this cohort, we plan to validate patient questionnaire responses against general practice electronic records, and assess the accuracy of these records for assessing data from physical examination and laboratory measurement, and for monitoring subsequent morbidity and mortality. This will determine whether computer derived records can be used reliably in the follow up, as well as the identification, of a cohort for studying the long term effects of postmenopausal HRT.
